Screener
Constellium CSTM R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Constellium in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Constellium’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 12:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001563411-26-000192
| (in millions of U.S. dollars) | Notes | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|---|
| Cost of sales (excluding depreciation and amortization) | (2,268) | (1,840) | (4,309) | (3,556) | |
| Depreciation and amortization | (84) | (82) | (167) | (160) | |
| Selling and administrative expenses | (101) | (88) | (198) | (166) | |
| Research and development expenses | (14) | (12) | (27) | (25) | |
| Other gains and losses – net | 4 | (39) | 4 | 34 | (1) |
| Finance costs – net | 5 | (28) | (29) | (56) | (56) |
| Income before tax | 214 | 56 | 486 | 118 | |
| Income tax expense | 6 | (66) | (20) | (142) | (44) |
Item 1. Financial Statements
FAQ
- What is Constellium's R&D?
- Constellium (CSTM) reported R&D of $14M in Q2 2026.
- How has Constellium's R&D changed year-over-year?
- Constellium's R&D increased by 16.7% year-over-year, from $12M to $14M.
- What is the long-term trend for Constellium's R&D?
- Over 3 years (2022 to 2025), Constellium's R&D has grown at a 3.5% compound annual growth rate (CAGR), from $46M to $51M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Constellium's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude